Phase 1 dose-escalation and expansion test of IUAb190708 for advanced or recurrent solid tumors

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

This trial tests IUAb190708, a new cytotoxic anti–PD‑L1 antibody given by IV, to see if it is safe and can kill tumors in adults with advanced or recurrent solid cancers.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: ImmunoUrchin (Industry-sponsored)
• Drugs / interventions: chemotherapy, Immunotherapy, radiation, prednisone
• Locations: 6 sites (Fuzhou, Fujian and 5 other locations)
• Trial ID: NCT07584954 on ClinicalTrials.gov

What this trial studies

This open-label Phase I dose-escalation and expansion trial administers IUAb190708 by intravenous infusion to adults with advanced or recurrent solid tumors to determine safety, tolerability, pharmacokinetics, and early signs of antitumor activity. IUAb190708 is a humanized IgG1 anti‑PD‑L1 designed to trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and direct NK‑cell–mediated tumor killing, and it may be given as monotherapy or combined with other cancer therapies. The study will use dose-escalation to identify MTD, DLTs, and an RP2D, with later expansion cohorts enriched for PD‑L1–positive tumors as specified. Tumor response will be measured by iRECIST and participants must provide tissue for PD‑L1 testing and pharmacodynamic assessments.

Who should consider this trial

Good fit: Adults aged 18–75 with histologically confirmed metastatic or locally advanced solid tumors, ECOG 0–1, life expectancy ≥3 months, at least one measurable lesion, adequate organ function, and (depending on cohort) PD‑L1 positivity are the intended participants.

Not a fit: Patients with ECOG >1, life expectancy under 3 months, inadequate organ function, or tumors lacking PD‑L1 expression where required are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, IUAb190708 could directly engage immune cells to kill PD‑L1–expressing tumors and offer a new option for patients whose cancers are refractory to current treatments.

How similar studies have performed: Other PD‑L1 antibodies have shown benefit by blocking PD‑1/PD‑L1, but using an ADCC‑capable anti‑PD‑L1 antibody like IUAb190708 is a newer approach with limited clinical data to date.

Eligibility criteria

Inclusion Criteria:

1. Male or female adult, age 18 - 75, understanding and voluntarily signing an informed consent form
2. A histologically confirmed diagnosis of Metastatic or locally advanced solid tumors, ineffective management of therapeutic regimen or currently no approved treatment available for the tumor, or unsuitable or refusing to receive standard treatment
3. In Phase Ia, for tumors with approved indications of anti PD-1/PD-L1 treatment, unrestricted to PD-L1 expression; for tumors that have not yet been approved for indications, positive expression of PD-L1 required. In Phase Ib, positive expression of PD-L1 is required
4. Subjects should provide fresh or archived tissue samples
5. Subjects must have at least one measurable lesion per iRECIST
6. Life expectancy ≥ 3 months
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
8. Adequate organ function, and no blood transfusion, erythropoietin (EPO), and granulocyte colony-stimulating factor at least 14 days before the study drug administration
9. All the female of child-bearing age must have a negative pregnancy test (unine or serum) during screening period and agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug. Male partners also must agree to use effective medical contraception from written informed consent to at least 6 months after the last administration of the study drug.

Exclusion Criteria:

1. Serious/active infection or infection requiring intravenous antibiotic treatment within 4 weeks prior to the first dose of the study drug
2. Receiving nitrosourea and mitomycin C within 6 weeks prior to the first dose of the study drug; receiving oral fluorouracil derivatives or small molecule targeted drugs within 2 weeks prior to the first dose or 5 half-lives of the drug (whichever is longer); receiving endocrine therapy, Immunotherapy, or Traditional Chinese Medicine for anti-tumor indications within 2 weeks prior to the first dose of the study drug; receiving other anti-tumor therapies, such as chemotherapy, radiation, biotherapy, besides as described above treatments, within 4 weeks prior to the first dose of the study drug
3. Having other primary active malignant tumors within 5 years prior to the first dose of the study drug
4. Having clinically significant cardiovascular diseases,
5. Primary tumors of central nervous system or CNS metastatic tumors that have failed local treatment. For asymptomatic or clinically stable symptoms without the need for steroid hormones and other treatments for CNS metastasis lasting ≥ 28 days, CNS tumors under stable condition, including new CNS metastasis without any syndrome, confirmed by imaging during screening period can be enrolled.
6. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
7. History of allogeneic organ transplant.
8. Known history of infection with Human Immunodeficiency Virus (HIV) or other acquired or congenital immunodeficiency.
9. Patients with serious psychiatric or medical condition that could interfere with medication adherence.
10. Receiving systemic corticosteroid therapy (prednisone \>10 mg/day or Bioequivalent dose of hydrocortisone) within 2 week prior to the first dose of trial treatment or receiving any other form of systemic immunosuppressive medication, except the condition as described below: treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids, or short-term (≤7 days) use of glucocorticoids for prophylactic treatment.
11. Active or history of autoimmune disease that requires systemic treatment within 2 years prior to enrollment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). But the subjects with the following diseases are allowed to be enrolled: Type I diabetes with stable condition after using fixed dose insulin; Autoimmune hypothyroidism that only requires hormone replacement therapy.
12. History of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial pneumonia or evidence of active pneumonia detected during chest CT scan screening.
13. Having experienced immune related adverse events of ≥ 3 grade during receiving any immunotherapy medication in the past.
14. Adverse reactions from previous anti-tumor treatments have not yet recovered to ≤1 grade per CTCAE 5.0 (except alopecia and other adverse reactions that the investigator determines that there is no safety risk)
15. Underwent major surgery within 4 weeks prior to the first dose of the study drug, or not fully recovered after surgery, or planned surgery within the expected participation time of the subject in the study or within 4 weeks after the last dose of the study drug.
16. Treponema pallidum antibody positive; active hepatitis B (HBsAg positive with HBV-DNA\>500IU/mL); active hepatitis C (except subjects with HCV antibody positive and HCV-RNA \<lower limit of clinical research organization).
17. Subjects with history or current evidence of any clinical condition or laboratory abnormality or other reasons are not suitable to participate in this clinical study by the investigator.
18. Female who are pregnant or breastfeeding
19. Subjects with history of other serious systemic diseases are not suitable to participate in this clinical study by the investigator.

Where this trial is running

Fuzhou, Fujian and 5 other locations

• Fujian Cancer Hospital — Fuzhou, Fujian, China (Recruiting)
• Anyang tumor hospital — Anyang, Henan, China (Recruiting)
• Cancer hospital of Shandong First Medical University — Jinan, Shandong, China (Recruiting)
• Fudan University Shanghai cancer center — Shanghai, China (Recruiting)
• Shanghai Pulmonary hospital — Shanghai, China (Recruiting)
• Shanghai Xinhua hospital — Shanghai, China (Recruiting)

Study contacts

• Study coordinator: Jun Zhou, Ph.D

Conditions Solid Tumor Cancer; Solid Tumor Cancer Treatment With Immunotherapy; cytotoxic antibody; PD-L1